Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites

Sakakura, Chouhei; Hagiwara, Akeo; Nakanishi, Masayoshi; Shimomura, Katsumi; Takagi, Tsuyoshi; Yasuoka, Rie; Fujita, Yoshifumi; Abe, Tatsuo; Ichikawa, Yasushi; Takahashi, Shinji; Ishikawa, Takashi; Nishizuka, Itaru; Morita, Tomoyuki; Shimada, Hiroshi; Okazaki, Yasushi; Hayashizaki, Yoshihide; Yamagishi, Hisakazu

doi:10.1038/sj.bjc.6600580

Cited by 74 publications

(66 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A 20 mg portion of total RNA extracted from each radioresistant subline was labelled with Cy3, and RNA from each parent cell line was labelled with Cy5 as described elsewhere (Sakakura et al, 2002). We used the RIKEN human cDNA microarray, which contains 21168 genes.…”

Section: Microarray Design Production and Hybridisationmentioning

confidence: 99%

“…We used the RIKEN human cDNA microarray, which contains 21168 genes. Hybridisation, washing, and scanning were carried out according to a published method (Sakakura et al, 2002). These slides were scanned on a ScanArray 5000 confocal laser scanner, and the images were analysed using IMAGENE (Bio Discovery, Los Angeles, CA, USA).…”

Section: Microarray Design Production and Hybridisationmentioning

confidence: 99%

See 1 more Smart Citation

Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation

et al. 2004

Self Cite

View full text Add to dashboard Cite

Section: Microarray Design Production and Hybridisationmentioning

confidence: 99%

Section: Microarray Design Production and Hybridisationmentioning

confidence: 99%

Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation

et al. 2004

Self Cite

View full text Add to dashboard Cite

“…(13,14) Using a highdensity cDNA microarray analysis, Sakakura et al demonstrated that CD44 expression is upregulated in gastric cancer cell lines established through metastasis to the peritoneal cavity. (15) The tissue that exists between mesothelial cells and the submesothelial capillary is named the peritoneal-blood barrier, which hinders the penetration of oxygen, nutrients and drugs from the submesothelial capillary to the peritoneal cavity. (16) After the attachment of peritoneal free cancer cells on the peritoneum, most free cancer cells die off due to the existence of the peritoneal-blood barrier.…”

Section: Molecular Mechanisms Of Peritoneal Disseminationmentioning

confidence: 99%

“…These non-fluoropyrimidine nucleosides may potentially help to improve the poor prognosis observed in patients with advanced cancers involving peritoneal dissemination. (Cancer Sci 2007; 98: [11][12][13][14][15][16][17][18] P eritoneal dissemination remains the most difficult type of metastasis to treat, and almost all surgeons believe that an operation is not indicated for such metastasis.…”

mentioning

confidence: 99%

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

et al. 2006

View full text Add to dashboard Cite

Peritoneal dissemination is the most common cause of metastasis from malignancies in the abdominal cavity. There are no standard treatments for peritoneal dissemination and the results are poor. The reasons for this are as follows: (1) no effective chemotherapeutic agents have been identified or developed; (2) surgical cytoreduction has little effect on survival improvement; and (3) the molecular mechanisms of peritoneal dissemination have not been clarified and no therapy against the target molecules has been developed. However, studies on the molecular mechanisms of peritoneal dissemination have elucidated some of the target molecules and the development of new multimodal therapies has also improved survival. Early postoperative intraperitoneal chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and neoadjuvant intraperitoneal-systemic chemotherapy have been newly developed, and a novel surgical therapy named peritonectomy has been proposed to perform complete cytoreduction of peritoneal dissemination. At present, these approaches appear to be effective therapeutic modalities for peritoneal dissemination. However, TS-1 and capecitabine have shown worthwhile results in recent clinical trials for patients with advanced gastric cancer. We recently found that newly developed antitumor cytosine nucleoside analogs show a survival advantage in peritoneal dissemination models using human cancer cells. These non-fluoropyrimidine nucleosides may potentially help to improve the poor prognosis observed in patients with advanced cancers involving peritoneal dissemination. (Cancer Sci 2007; 98: 11-18) P eritoneal dissemination remains the most difficult type of metastasis to treat, and almost all surgeons believe that an operation is not indicated for such metastasis.(1-3) Systemic chemotherapy tends to have little effect on the treatment of peritoneal dissemination, because the peritoneal-blood barrier existing between mesothelial cells and the submesothelial capillary hinders drug distribution throughout the peritoneal cavity. Recent advances in the studies of new drugs and multimodal therapies have proposed the therapeutic potency for advanced cancer with peritoneal dissemination. Neoadjuvant chemotherapy is also known to reduce the tumor burden, thus resulting in a stage reduction. As a result, the incidence of complete cytoreduction may increase after neoadjuvant chemotherapy. A new type of neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) has been developed to increase the rate of complete cytoreduction. The complete removal of peritoneal dissemination is an independent prognostic factor. A peritonectomy is a novel surgical procedure by which complete cytoreduction for peritoneal dissemination is performed.(5-8) These approaches are now being carried out as treatment modalities for peritoneal dissemination from appendiceal, colon and gastric cancer. Furthermore, several recent phase II studies that evaluated the efficacy of new anticancer drugs including taxanes, TS-1 and capecitabine have shown p...

show abstract

“…Integrins are composed of two different subunits, ␣ and ␤, which are noncovalently bound into ␣␤ complexes (2)(3)(4). Particularly, the expression of ␣ v ␤ 3 integrin (ABI) in tumor cells undergoing angiogenesis and on the epithelium of tumor-induced neovasculature alters the interaction of cells with the extracellular matrix, thereby increasing tumorigenicity and invasiveness of cancers (5)(6)(7)(8)(9).…”

mentioning

confidence: 99%

Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression

Achilefu

Bloch²,

Markiewicz³

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

119

113

View full text Add to dashboard Cite

mouse ͉ optical imaging ͉ RGD peptides ͉ tumor ͉ near-infrared A ngiogenesis, the formation of new blood vessels, is the cardinal feature of virtually all malignant tumors (1). Because of this commonality, probing tumor-induced angiogenesis and associated proteins is a viable approach to detect and treat a wide range of cancers. Angiogenesis is stimulated by integrins, a large family of transmembrane proteins that mediate dynamic linkages between extracellular adhesion molecules and the intracellular actin skeleton. Integrins are composed of two different subunits, ␣ and ␤, which are noncovalently bound into ␣␤ complexes (2-4). Particularly, the expression of ␣ v ␤ 3 integrin (ABI) in tumor cells undergoing angiogenesis and on the epithelium of tumor-induced neovasculature alters the interaction of cells with the extracellular matrix, thereby increasing tumorigenicity and invasiveness of cancers (5-9).Numerous studies have shown that ABI and more than seven other heterodimeric integrins recognize proteins and low molecular weight ligands containing RGD (arginine-glycineaspartic acid) motifs in proteins and small peptides (10). Based on structural and bioactivity considerations, cyclic RGD peptide ligands are preferentially used as delivery vehicles for molecular probes for imaging (8,(11)(12)(13) and treating (14-17) ABI-positive tumors and proliferating blood vessels. Until recently, most of the in vivo imaging studies were performed with radiopharmaceuticals because of the high sensitivity and clinical utility of nuclear imaging methods. Particularly, the use of small monoatomic radioisotopes does not generally interfere with the biodistribution and bioactivity of ligands. Despite these advantages, nuclear imaging is currently only performed in specialized centers because of regulatory, production, and handling issues associated with radiopharmaceuticals. Optical imaging is an alternative but complementary method to interrogate molecular processes in vivo and in vitro.Optical imaging for biomedical applications typically relies on activating chromophore systems with low energy radiation between 400 -and 1,500-nm wavelengths and monitoring the propagation of light in deep tissues with a charge-coupled device camera or other point source detectors (18). Molecular optical imaging of diseases with molecular probes is attractive because of the flexibility of altering the detectable spectral properties of the probes, especially in the fluorescence detection mode. The probes can be designed to target cellular and molecular processes at functional physiological concentrations. For deep-tissue imaging, molecular probes that are photoactive in the near-infrared (NIR) instead of visible wavelengths are preferred to minimize background tissue autof luorescence and light attenuation caused by absorption by intrinsic chromophores (19). In contrast to radioisotopes, the NIR antennas are usually large heteroatomic molecules that could impact the biodistribution and activity of conjugated bioactive ligands. However, previous s...

show abstract

Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites

Cited by 74 publications

References 57 publications

Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation

Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression

Contact Info

Product

Resources

About